RO7204239 + risdiplam

RO7204239 + risdiplam is an investigational combination therapy being evaluated for the treatment of spinal muscular atrophy (SMA). RO7204239 is an investigational monoclonal antibody targeting myostatin, a negative regulator of skeletal muscle growth. By inhibiting myostatin, RO7204239 aims to increase muscle size and strength. Risdiplam is an approved oral small molecule that acts as an SMN2 mRNA splicing modifier, increasing the production of survival motor neuron (SMN) protein, deficient in SMA. The rationale for the combination is that dual therapy may provide complementary mechanisms: risdiplam improves SMN protein concentration to maintain motor neurons, while RO7204239 increases muscle size and strength, potentially leading to greater improvements in motor function than either agent alone[1][3][5][7].

Other names

RO7204239 + risdiplamEvrysdi + RO7204239